Home » Solid tumors. From new study potential strategy to improve Car-T therapy

Solid tumors. From new study potential strategy to improve Car-T therapy

by admin

By targeting two gene regulators of inflammation, the engineered T cells expand and last longer inside the solid tumor, raising the possibility that they could have the same therapeutic effect they have in blood cancers. It is the concept on which a new approach against solid tumors is based, being studied in the preclinical phase, developed by researchers at the University of Pennsylvania.

17 MAR – Targeting two regulators that control inflammation-related gene functions leads to a tenfold expansion of T cells, with an increase in anti-tumor immune activity and their persistence at the tumor site. It is the concept on which a new approach against solid tumors is based, being studied in the preclinical phase, developed by researchers at the University of Pennsylvania. The methodology has been described in Proceedings of the National Academy of Sciences (PNAS).

Since the first CAR-T cell treatment was approved, personalized cell treatments have revolutionized blood cancer therapy, but remain ineffective against solid tumors. One of the obstacles in this application is the phenomenon known as T-cell ‘burnout’, in which persistent exposure to antigen causes immune cells to lose their ability to respond to the tumour.

I study
Using the CRISPR-Cas9 technique, the research team went on to inhibit the inflammation regulatory genes Regnase-1 and Roquin-1, individually or together, in T cells from healthy donors, with two different immune receptors currently in phase I of clinical study: the mesothelin-targeting M5 CAR (mesoCAR) and the NY-ESO-1-targeting 8F TCR (NYESO TCR). After editing, the cells were expanded and infused into animal models of solid tumors, where the researchers observed that double inhibition increased the amount of engineered T cells by at least tenfold, and showed increased antitumor activity. and increased life span of engineered T cells.

See also  Crisis First aid: neither tips nor patches, urgent and long-term structural responses are needed

Source: Proceedings of the National Academy of Sciences 2023

March 17, 2023
© breaking latest news


Other articles in Science and Drugs

image_1

image_2

image_3

image_4

image_5

image_6

Quotidianosanità.it

Online newspaper
of health information.

QS Editions srl

P.I. 12298601001

Registered office:
Via Giacomo Peroni, 400
00131 – Roma

Operational headquarters:
Via della Stelletta, 23
00186 – Roma

Site Manager

Luciano Fassari

Editorial director
Francesco Maria Avitto

President
Ernesto Rodriguez

    Joint Venture

  • SICS srl
  • Editions
    Health Communication
    srl

Copyright 2013 © QS Edizioni srl. All rights reserved
– P.I. 12298601001
– registration in the ROC n. 23387
– registration with the Court of Rome n. 115/3013 of 05/22/2013

All rights reserved.
Policy privacy

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy